Low circulating coenzyme Q10 during acute phase is associated with inflammation, malnutrition, and in-hospital mortality in patients admitted to the coronary care unit

Abstract

Coenzyme Q10 (CoQ10) has a potential role in the prevention and treatment of heart failure through improved cellular bioenergetics. In addition, it has antioxidant, free radical scavenging, and vasodilatory effects that may be beneficial. Although critical illness in intensive care unit is associated with decreased circulating CoQ10 levels, the clinical significance of CoQ10 levels during acute phase in the patients of cardiovascular disease remains unclear. We enrolled 257 consecutive cardiovascular patients admitted to the coronary care unit (CCU). Serum CoQ10 levels were measured after an overnight fast within 24 h of admission. We examined the comparison of serum CoQ10 levels between survivors and in-hospital mortalities in patients with cardiovascular disease. Serum CoQ10 levels during the acute phase in patients admitted to the CCU had similar independent of the diagnosis. CoQ10 levels were significantly lower in patients with in-hospital mortalities than in survivors (0.43 ± 0.19 vs. 0.55 ± 0.35 mg/L, P = 0.04). In patients admitted to the CCU, CoQ10 levels were negatively associated with age and C-reactive protein levels, and positively associated with body mass index, total cholesterol, and high-density lipoprotein cholesterol levels. Low CoQ10 levels correlated with low diastolic blood pressure. Multivariate logistic regression analysis demonstrated that low CoQ10 levels were an independent predictor of in-hospital mortality. Low serum CoQ10 levels during acute phase are significantly associated with cardiovascular risk and in-hospital mortality in patients admitted to the CCU.

Aging-Related Disorders and Mitochondrial Dysfunction: A Critical Review for Prospect Mitoprotective Strategies Based on Mitochondrial Nutrient Mixtures

“…The authors suggested that CoQ10 deficiency may contribute to the pathogenesis of MSA, and that increasing CoQ10 levels by supplementation or upregulation of its biosynthesis may represent a novel treatment strategy for MSA patients. Analogous conclusions were provided by Shimizu et al [ 31 ], and by Hargreaves and Mantle [ 32 ] that focused on the potential role of CoQ10 supplementation in the treatment of tissue fibrosis and cardiovascular risk, by improving cardiovascular function and reducing the risk of cardiovascular-associated mortality.…”

Serum Coenzyme Q10 Levels are Decreased in Critically-Ill Septic Patients: Results From a Preliminary Study

“…This might be due to the fact that a substantial proportion of our patients was admitted to the ICU due to trauma, which usually relates to relatively young ages. Prior studies showed that CoQ10 correlated positively with BMI and the levels of cholesterol (Shimizu et al, 2017), suggesting that low CoQ10 reflects malnutrition. In our study, there was a statistically significant positive correlation with total cholesterol and a trend towards a positive correlation with albumin levels, which to some extent express nutritional status.…”

Age-related mitochondrial dysfunction as a key factor in COVID-19 disease

“…Another compound used as supplement that modulates several aspects of metabolism and mitochondrial mechanisms is CoQ 10 . Low levels of plasma CoQ 10 have been associated with inflammation and mortality in CVD patients (Shimizu et al, 2017). Furthermore, supplementation with CoQ 10 can prevent the processes related to chronic oxidative stress and inflammation during aging (Lopez-Lluch, 2020;Lopez-Moreno et al, 2018).…”

“…Furthermore, supplementation with CoQ 10 can prevent the processes related to chronic oxidative stress and inflammation during aging (Lopez-Lluch, 2020;Lopez-Moreno et al, 2018). Many in vitro and clinical studies indicate that CoQ10 is a promising anti-inflammatory molecule in metabolic and age-related diseases (Schmelzer et al, 2010;Shimizu et al, 2017;Suárez-Rivero et al, 2019;Yubero-Serrano et al, 2012) although the variability in the bioavailability of this compound in humans can affect the conclusions in different clinical studies (Lopez-Lluch et al, 2019).…”